Kisqali 200 MG daily dose UU 21S
Ended Awarded
- Contract number
- SPE2DB25FJV07
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $36,863
Award facts
- Contract value 100% obligated
- $36,863.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $36,863.04 delivery order to AmerisourceBergen Drug Corp for Kisqali 200 mg daily dose in a 21-count unit pack on September 8, 2025, with completion scheduled for September 9, 2025. This firm fixed-price contract utilizes a competitively awarded, non-set-aside mechanism and reflects AmerisourceBergen's role as a critical pharmaceutical supplier within the federal medical procurement system. The award is executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999,999,999 ceiling value and extends through December 2026.
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor supporting military and veteran healthcare systems across multiple therapeutic domains. The DLA Medical Supply Chain utilizes the company's comprehensive product portfolio to fulfill federal medical supply needs, ranging from specialty medications and vaccines to generic pharmaceuticals and medical devices. The SPE2DX indefinite delivery vehicle provides a flexible procurement mechanism enabling the company to supply pharmaceutical products and medical supplies to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems globally. This delivery order for Kisqali, a cancer treatment medication, exemplifies the breadth of pharmaceutical commodities distributed through AmerisourceBergen's federal contracts supporting military medicine.
Quick answers
Who was awarded contract SPE2DB25FJV07?
SPE2DB25FJV07 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on September 8, 2025.
How much is contract SPE2DB25FJV07 worth?
The government has obligated $36,863 on SPE2DB25FJV07.
Is contract SPE2DB25FJV07 an order under another contract?
Yes. SPE2DB25FJV07 is a delivery order under SPE2DB22D2206, an indefinite delivery contract.
Was contract SPE2DB25FJV07 competed?
The extent of competition for SPE2DB25FJV07 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award